ANI Pharmaceuticals CFO sells 2,850 shares

The plan was adopted on March 6, 2026, and the reported sale price reflects trades across a $72.18-to-$73.29 range.

Available on EDGAR 10/30/2026 - 04:36 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:36 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) SVP & CFO Stephen P. Carey reported selling 2,850 shares of Common Stock on October 29, 2026, at a weighted-average price of $72.87 per share. The sales were made under a Rule 10b5-1 trading plan adopted on March 6, 2026. The reported price reflects multiple trades ranging from $72.18 to $73.29; Carey directly held 166,143 shares after the sale.

Insider Trade Summary 10b5-1

Net Seller: 2,850 shares

Net Sell 1 txn

Insider CAREY STEPHEN P.

Role SVP & CFO

Sold 2,850 shs ($208K)

Share of Position Sold 1.7%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,850	$72.87	$208K

Holdings After Transaction: Common Stock — 166,143 shares (Direct)

Holdings Before and After: Common Stock, 168,993 to 166,143 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. F2. The shares were sold in multiple trades at prices ranging from $72.18 to $73.29. The price reported above reflects the weighted average sales price.

Key Figures

Common shares sold: 2,850 shares Weighted-average sale price: $72.87 per share Trade price range: $72.18–$73.29 per share +1 more

4 metrics

Common shares sold 2,850 shares October 29, 2026

Weighted-average sale price $72.87 per share October 29, 2026

Trade price range $72.18–$73.29 per share Multiple trades reported for the sale

Direct shares held after sale 166,143 shares After the October 29, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average sales price

2 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"reflects the weighted average sales price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANIP shares did Stephen P. Carey sell, and at what price?

Stephen P. Carey sold 2,850 shares on October 29, 2026, at a weighted-average price of $72.87 per share. The multiple trades ranged from $72.18 to $73.29.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/29/2026		S(1)		2,850	D	$72.87(2)	166,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

2. The shares were sold in multiple trades at prices ranging from $72.18 to $73.29. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)